NewsBenzingaアストラゼネカの補足生物医薬品ライセンス申請(Imfinzi(デュルバルマブ)とEnfortumab Vedotinの併用)が、筋肉浸潤性膀胱癌でシスプラチンベースの化学療法が適応外または拒否した患者に対し、FDAが受理し、優先審査を付与します。 アストラゼネカの補足生物医薬品ライセンス申請(Imfinzi(デュルバルマブ)とEnfortumab Vedotinの併用)が、筋肉浸潤性膀胱癌でシスプラチンベースの化学療法が適応外または拒否した患者に対し、FDAが受理し、優先審査を付与します。 Benzinga 2026.09.25 10:00 (GMT+0) Open on Benzinga Other news Ramp in Talks to Raise at Least $1 Billion at Valuation of Up to $75 Billion How Everyday Investors Are Playing the Nvidia Drama Curve: Fee Conversion Contract Loses $38.2K in Attack, Disabled With Replacement Planned Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript Nvidia Tops Sales Forecast After Huang's Resignation Bill Gates Has Earned $2.6 Billion in Dividends From a Landfill Stock the EPA Keeps Citing for Methane Leaks, and a Filing Shows He Just Bought 3.7M More Shares
Bill Gates Has Earned $2.6 Billion in Dividends From a Landfill Stock the EPA Keeps Citing for Methane Leaks, and a Filing Shows He Just Bought 3.7M More Shares